In line with our screen data, Usp7, Metap1, Metap2, and MMP17 could be validated as depletion hits in vitro, whereby targeting reduced MTT viability and competitive breast cancer cell growth (Figure 6). The gene discussed is METAP1; the disease is breast carcinoma.